Mabanal, Jessa .

HRN: 28-60-51  Sex: Female

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
02/22/2026
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
02/22/2026
03/01/2026
IV
2.25g
Q8H
UTI
Pending Pharmacy Acceptance 

 Indication:  Empiric    Type of Infection:  Urinary Tract    Compliance to guidelines: